

<b>Reference:</b>	FOI.967.19
<b>Subject:</b>	Multiple Myeloma
<b>Date of Request:</b>	12 June 2019

**Requested**

1. Does your trust treat adult multiple myeloma [MM] ? - if you refer your multiple myeloma patients to another centre, please state which.
2. If yes, then how many MM patients, have been treated in the past 6 months with the following;
  - Bortezomib [Velcade]
  - Carfilzomib [Kyprolis]
  - Ixazomib [Ninlaro]
  - Lenalidomide [Revlimid]
  - Daratumumab [Darzalex]
  - Melphalan, prednisolone and thalidomide (known as MPT)
  - Cyclophosphamide, thalidomide and dexamethasone (known as CTD)
  - Pomalidomide [Imnovid]
3. If you are able to split by therapy line for question 2, please indicate the number of patients above being treated, 1st line and 2nd line.
4. Does your trust treat adult/paediatric primary immune thrombocytopenia patients [ITP] ? - if you refer your adult/paediatric primary immune thrombocytopenia patients to another centre, please state which.
5. If yes, then of the treated adult/paediatric primary immune thrombocytopenia patients, how many are on the following;
  - Eltrombopag [Revolade]
  - Romiplostim [Nplate]
6. At what line of treatment would you currently use a Thrombopoietin Receptor Agonist [TPO] (Eltrombopag [Revolade], Romiplostim [Nplate]) in an immune thrombocytopenia purpura [ITP] patient.
  - 1st
  - 2nd
  - 3rd
  - 4th
  - Unknown
7. Do you treat patients with a Thrombopoietin Receptor Agonist TPO for the following diseases?
- 7a. Chronic hepatitis C virus (HCV) infection for the treatment of thrombocytopenia, where the degree of thrombocytopenia is the main factor preventing the initiation or limiting the ability to maintain optimal interferon-based therapy
  - Eltrombopag [Revolade]
  - Romiplostim [Nplate]

7b. Acquired severe aplastic anaemia (SAA) who were either refractory to prior immunosuppressive therapy or heavily pre-treated and are unsuitable for haematopoietic stem cell transplantation

- Eltrombopag [Revolade]
- Romiplostim [Nplate]

7c. Chemotherapy induced thrombocytopenia (CIT)

- Eltrombopag [Revolade]
- Romiplostim [Nplate]
- 7d myelodysplastic syndromes (MDS)
- Eltrombopag [Revolade]
- Romiplostim [Nplate]

8. Over the past 6 months [latest possible], how many chronic lymphocytic leukaemia (CLL) patients have you treated?

9. If possible how many CLL patients treated were new to therapy in the past 3 months?

10. How many chronic lymphocytic leukaemia patients, have been treated in the past 6 months with the following;

- Fludarabine (Fludara), cyclophosphamide (Cytosan), and rituximab (known as FCR)
- Bendamustine and rituximab (known as BR)
- Ibrutinib [Imbruvica]
- Chlorambucil
- Venetoclax
- Obinutuzumab
- Idelalisib
- Fludarabine and rituximab (known as FR)
- High-dose prednisone and rituximab
- Pentostatin (Nipent), cyclophosphamide, and rituximab (known as PCR)
- Alemtuzumab (Campath) with rituximab

**Response:**

Hywel Dda University Health Board (UHB) is unable to provide you with the information requested as it is estimated that the cost of answering your request would exceed the “appropriate level” as stated in the Freedom of Information (Fees and Appropriate Limit) Regulations 2004. The “appropriate level” represents the estimated cost of one person spending 18 hours or (2 ½ working days) in determining whether the UHB holds the information, and locating, retrieving and extracting the information.

The Chemocare team, who hold a central record of cancer treatments, is based within Swansea Bay University Health Board (SBUHB). In order to provide you with the information requested, the UHB would be required to conduct a manual trawl of all cancer patients’ medical records to establish the type of cancer diagnosed and therapies used to treat the patients. It is estimated that conducting this search would take longer than the 18 hour ‘appropriate limit’ as stated within the Act.

The UHB is therefore applying an exemption under Section 12 of the Freedom of Information Act 2000, which provides an exemption from a public authority’s obligation to comply with a request for information where the cost of compliance is estimated to exceed the *appropriate limit*.

Under section 16 of the Freedom of Information Act, the UHB has an obligation to provide advice and assistance.

We would therefore recommend that you redirect your request to the Freedom of Information Team in SBUHB who may be able to help you with your enquiry: -

[FOIA.Requests@wales.nhs.uk](mailto:FOIA.Requests@wales.nhs.uk) or alternatively, you can contact: FOIA Team, Swansea Bay University Health Board, Health Board Headquarters, 1 Talbot Gateway, Port Talbot, SA12 7BR.